The Pharma Letter5d
Chengdu Baiyu enters into a license deal with Novartis
Chengdu Baiyu Pharmaceutical yesterday announced that it has entered into an exclusive license agreement with Swiss pharma ...
FierceBiotech5d
Novartis pays China's Baiyu $70M upfront, with $1.1B chaser, for small molecule cancer candidate
Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...
Yahoo Finance4d
PTC rebuffed again by EMA; Novartis licenses China-based biotech’s cancer drug
Jacob Bell Novartis is paying China-based Chengdu Baiyu Pharmaceutical $70 million for global licensing rights to a single small molecule cancer drug. The deal, which includes up to $1.1 billion ...
PipelineReview.com4d
Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor
CHENGDU, China I October16, 2024 I Chengdu Baiyu Pharmaceutical Co., Ltd. ("Baiyu") today announced that it has entered into an exclusive license ...
FiercePharma4d
Fierce Pharma Asia—Lilly's China expansions; Gilead's scrapped MASH deal; Leqembi's vial scrutiny
Eli Lilly is making a series of investments in China to support its manufacturing and R&D operations. Gilead Sciences has ...